Collaborative Model for Acceleration of Individualized Therapy of Colon Cancer
Technical Report,15 Sep 2011,14 Sep 2015
Regents Of The University Of Colaroda Aurora United States
Pagination or Media Count:
Colorectal cancer CRC represents a major health burden, and is the third leading cause of cancer deaths in the U.S. In the past decade, the median survivalamong patients with metastatic CRC has significantly improved, primarily due the development of active chemotherapeutic regimens that include biologicalagents. However, despite this success, patients soon run out of therapeutic options and receive salvage therapy that results in only a few weeks of diseasestability. We have proposed to employ a team science, systems biology based approach to rapidly identify novel anti-cancer agents and individualizetherapeutic strategies in preclinical CRC models. In this Year 1 Progress report, we will present the tasks and key accomplishments achieved within thisperiod of time. In brief, we have completed in vitro testing on a large panel of CRC cell lines for six novel anti-cancer agents. We have completed baselinegene expression profiling of our CRC cell lines panel and patient-derived CRC tumor explant models by high-throughput RNA sequencing approach. We haveinitiated the in vivo cell line derived xenograft models to test the efficacy of these novel anti-cancer agents and in the process of determining the down streameffectors of these targets by immunoblotting assays. Our research findings for RNA-seq analaysis will be presented at the 24th EORTC-NCI-AACRSymposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland November 6-9, 2012. In summary, we have accomplished all the tasks that weproposed in year 1.